FibroBiologics Engages Southern Star Research As Clinical Research Organization In Australia, Initial CRO Services Will Include Preparatory Work For A Phase 1/2 Clinical Trial Utilizing Product Candidate, CYWC628, To Treat Diabetic Foot Ulcers
Portfolio Pulse from Benzinga Newsdesk
FibroBiologics has partnered with Southern Star Research to conduct a Phase 1/2 clinical trial in Australia for their product candidate CYWC628, aimed at treating diabetic foot ulcers.
September 19, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FibroBiologics has engaged Southern Star Research for clinical trial services in Australia, focusing on their product CYWC628 for diabetic foot ulcers. This partnership marks a significant step in advancing their clinical trials.
The engagement with Southern Star Research for a clinical trial is a positive development for FibroBiologics, as it advances their product candidate CYWC628. This could lead to potential breakthroughs in treating diabetic foot ulcers, which may positively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100